Recombinant lubricin

Drug Profile

Recombinant lubricin

Alternative Names: ECF 843; lubricin recombinant; rh-lubricin

Latest Information Update: 03 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Lubris BioPharma
  • Developer Dompe Farmaceutici; Lubris BioPharma
  • Class Eye disorder therapies; Glycoproteins; Recombinant proteins
  • Mechanism of Action Glycoprotein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Dry eyes
  • Preclinical Osteoarthritis

Most Recent Events

  • 26 Jan 2017 Dompé Farmaceutici plans a pre-market study for Dry eyes in Italy (Ophthalmic, Drops) (NCT03031327)
  • 20 Sep 2016 Efficacy data from a Clinical trial in Dry eyes released by Lubris Biopharma (NCT02510235)
  • 25 Jul 2016 Preclinical trials in Dry eyes in USA before July 2016(unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top